外周Ｔ细胞淋巴瘤ＭＵＭ１／ＩＲＦ４蛋白的表达及其临床意义

目的　研究ＭＵＭ１／ＩＲＦ４蛋白在外周Ｔ细胞淋巴瘤（ＰＴＣＬ）中的表达及临床意义。方法　应用免疫组织化学ＳＰ法检测４６例初治、诊断及分型明确的ＰＴＣＬ患者组织标本中ＭＵＭ１／ＩＲＦ４的表达，分析其表达与患者的临床病理特征、近期疗效及生存的关系。结果　４６例ＰＴＣＬ患者的ＭＵＭ１／ＩＲＦ４阳性表达率为７８.２％。ＭＵＭ１／ＩＲＦ４阴性表达者的有效率为８０.０％，高于阳性者的４６.７％（Ｐ＜０.０５）。全组患者的中位生存期为３１.９个月（９５％ＣＩ：２６～３４个月），ＭＵＭ１／ＩＲＦ４阴性表达者为２８.０个月，阳性表达者为１５.０个月，差异有统计学意义（Ｐ＝０.０２６）。ＭＵＭ１／ＩＲＦ４阴性表达者的中位无进展生存期为１９.０个月，阳性表达者为１１.７个月，差异有统计学意义（Ｐ＝０.０４１）。结论　ＭＵＭ１／ＩＲＦ４蛋白在ＰＴＣＬ中过表达提示预后不良，可作为判断ＰＴＣＬ预后的指标之一。

Expression and clinical significance of MUM1/IRF4 protein in peripheral T-cell lymphoma

Objective To investigate the expression of MUM1/IRF4 protein in peripheral T-cell lymphoma（PTCL） and its clinical significance.Methods The expression of MUM1/IRF4 protein in 46 specimens of PTCL was detected by SP immunohistochemistry.The correlations of MUM1/IRF4 protein expression to clinical features,objective response,and overall survival of PTCL patients were analyzed.Results Of the 46 patients,36（78.2%） were MUM1/IRF4-positive expression.The effective rate was significantly higher in MUM1/IRF4-negative patients than in MUM1/IRF4-positive patients（80.0% vs.46.7%,P0.05）.The median overall survival was 31.9 months（95%CI：26-34 months）with 28.0 months in MUM1/IRF4-negative group and 15.0 months in MUM1/IRF4-positive group.The difference was significant between the two groups（P=0.026）.The median progression-free survival was significantly higher in MUM1/IRF4-negative patients than in MUM1/IRF4-positive patients（19.0 vs.11.7 month,P=0.041）.Conclusion Over-expression of MUM1/IRF4 protein is related to poor prognosis of PTCL;it may be a potential prognostic index of PTCL.